Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue (BATNAD)

University of Turku

Status

Not yet enrolling

Conditions

Obesity, Abdominal

Treatments

Other: Placebo

Dietary Supplement: NAD+ precursor

Study type

Interventional

Funder types

Other

Identifiers

NCT06627868

VARHA/13032/13.02.02/2024

Details and patient eligibility

About

A fully functional brown fat helps maintain a healthy weight and decreases the risk of metabolic diseases such as type II diabetes (T2DM). Unfortunately, in human adults, the functionality of brown fat declines with age, and it is one of the reasons for gaining unhealthy weight, particularly around the waistline (central obesity). Currently, we do not clearly understand the reasons for the decline in brown fat functionality. It is possible that the decline in the availability of the molecule Nicotinamide Adenine Dinucleotide (NAD+), which is central to several metabolic processes, plays a role in the decline in brown fat metabolism. This project will clarify whether NAD+-based molecular-targeted therapies for the enhancement of whole-body insulin sensitivity and brown fat metabolism will be successful in adult humans, which will eventually be an important target for reducing the development of obesity and its comorbidities such as T2DM.

Enrollment

68 estimated patients

Sex

All

Ages

30 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Willingness to provide informed consent to participate in the BATNAD study
Must be able to read and speak English/Finnish/Swedish well enough to completely understand the instructions and provide informed consent
Age 30-55 (sedentary lifestyle)
BMI = 18-25 kg/m2 (normal-weight subjects)
BMI ≥ 28 kg/m2 and waist circumference more than 100 cm in men and more than 90 cm in women (subjects with obesity)

Exclusion criteria

Inability to have PET/CT (claustrophobia, metal implants, recent tattoo including metal components, weight > 200 kg)
Pregnancy and pregnancy related conditions (postpartum/lactation during the last 12 months, or planning to become pregnant soon)
Major alterations in the menstrual cycle (e.g., amenorrhea)
Use of nicotine based products
Hypo- or hyper- thyroidism (medical history, TSH, T3 or T4 levels out of the normal range)
Diabetes mellitus (fasting Hb1Ac >6.5% or fasting glycaemia> 7.0 mmol/)
Abnormal oral glucose tolerance test (2h OGTT > 11.1 mmol/L)
Hypertension (blood pressure > 160/100 mmHg)
Abnormal cardiovascular status (arrhythmia and/or long QTc in ECG, abnormal cardiac murmur, previous history of cardiovascular disease)
Abnormal coagulopathy (e.g., clotting abnormality)
Malignancies
Immunological, autoimmune and primary/secondary immunodeficiency disorders (including or not any active treatment)
Virus or bacterial infection (both asymptomatic and symptomatic picture) within the 45 days prior to the study start
Vaccination within the 45 days prior to the study start
Episode of fever or major surgery, burns and traumas within the month prior to the study start
Chronic infections requiring chronic antibiotic or anti-viral treatment
Whole blood donation in the last 3 months (>400 mL of blood) or plans for blood donation during the entire protocol period
Weight change (intentional or not) over the last 6-months more than 5% of body weight, or plan to lose weight during the study
Allergy to lidocaine or epinephrine, or other local anaesthetics
Previous participation to studies where PET or CT method is used
Use of any medication that, in the opinion of local clinician/researcher, would negatively impact or mitigate full participation and completion, or could influence the study results. This especially applies to the use of β or α adrenergic receptors agonists/antagonists (e.g., β-blockers).
Any other cardiovascular, pulmonary, orthopaedic, neurologic, psychiatric or other conditions that, in the opinion of the local clinician/researcher, would preclude participation and successful completion of the protocol, or that would negatively impact or mitigate participation in and completion of the protocol